{
    "id": "62eab598-3e2d-4384-af52-c381674f9f28",
    "indications": {
        "text": "fluticasone propionate salmeterol inhalation powder combination product containing corticosteroid long-acting beta 2 -adrenergic agonist ( laba ) indicated : \u2022 twice-daily treatment asthma patients aged 4 years older . ( ) \u2022 maintenance treatment airflow obstruction reducing exacerbations patients chronic obstructive pulmonary disease ( chronic obstructive pulmonary disease ) . ( ) important limitation : indicated relief acute bronchospasm . ( , )",
        "doid_entities": [
            {
                "text": "asthma (DOID:2841)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2841"
            },
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "fluticasone propionate salmeterol inhalation powder administered 1 inhalation twice daily orally inhaled route . inhalation , patient rinse his/her mouth water without swallowing help reduce risk oropharyngeal candidiasis . frequent greater number inhalations ( 1 inhalation twice daily ) prescribed strength fluticasone propionate salmeterol inhalation powder recommended patients likely experience effects higher doses salmeterol . patients using fluticasone propionate salmeterol inhalation powder additional laba reason [ ( error ! hyperlink reference valid . , ) ] .",
        "doid_entities": [
            {
                "text": "oropharyngeal candidiasis (DOID:2271)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2271"
            },
            {
                "text": "candidiasis (DOID:1508)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1508"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fluticasone propionate salmeterol inhalation powder , usp 100 mcg/50 mcg supplied disposable gray plastic inhaler containing foil blister strip 60 blisters . inhaler packaged plastic-coated , moisture-protective foil pouch ndc 68788-8704-6 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] store dry place away direct heat sunlight . keep reach children . fluticasone propionate salmeterol inhalation powder stored inside unopened moisture-protective foil pouch removed pouch immediately initial . discard fluticasone propionate salmeterol inhalation powder 1 month opening foil pouch counter reads \u201c 0 \u201d ( blisters used ) , whichever comes first . inhaler reusable . attempt take inhaler apart .",
    "adverseReactions": "fluticasone propionate salmeterol inhalation powder contraindicated following conditions : \u2022 primary treatment status asthmaticus acute episodes asthma chronic obstructive pulmonary disease intensive measures required [ ( ) ] . \u2022severe hypersensitivity milk proteins demonstrated hypersensitivity fluticasone propionate , salmeterol , excipients [ ( ) , ( ) , description ( ) ] .",
    "ingredients": [
        {
            "name": "SALMETEROL XINAFOATE",
            "code": "6EW8Q962A5",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9012"
        },
        {
            "name": "FLUTICASONE PROPIONATE",
            "code": "O2GMZ0LF5W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31441"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        }
    ],
    "organization": "Preferred Pharmaceuticals Inc.",
    "name": "fluticasone propionate and salmeterol",
    "effectiveTime": "20250514",
    "indications_original": "Fluticasone propionate and salmeterol inhalation powder is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: \u2022 Twice-daily treatment of asthma in patients aged 4 years and older. () \u2022 Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). () Important Limitation of Use: Not indicated for relief of acute bronchospasm. (, )",
    "contraindications_original": "Fluticasone propionate and salmeterol inhalation powder should be administered as 1 inhalation twice daily by the orally inhaled route only. After inhalation, the patient should rinse his/her mouth with water without swallowing to help reduce the risk of oropharyngeal candidiasis.\n                  More frequent administration or a greater number of inhalations (more than 1 inhalation twice daily) of the prescribed strength of fluticasone propionate and salmeterol inhalation powder is not recommended as some patients are more likely to experience adverse effects with higher doses of salmeterol. Patients using fluticasone propionate and salmeterol inhalation powder should not use additional LABA for any reason [see Warnings and Precautions (\n                     Error! Hyperlink reference not valid.\n                     , \n                     )].",
    "warningsAndPrecautions_original": "Fluticasone Propionate and Salmeterol Inhalation Powder, USP\n                  \n                  100 mcg/50 mcg is supplied as a disposable gray plastic inhaler containing a foil blister strip with 60 blisters. The inhaler is packaged in a plastic-coated, moisture-protective foil pouch NDC 68788-8704-6    \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Store in a dry place away from direct heat or sunlight. Keep out of reach of children. \n                  Fluticasone propionate and salmeterol inhalation powder should be stored inside the unopened moisture-protective foil pouch and only removed from the pouch immediately before initial use. Discard fluticasone propionate and salmeterol inhalation powder 1 month after opening the foil pouch or when the counter reads \u201c0\u201d (after all blisters have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.",
    "adverseReactions_original": "The use of fluticasone propionate and salmeterol inhalation powder is contraindicated in the following conditions:\n                  \n                     \n                        \u2022\n                        Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required [see Warnings and Precautions (\n                           )].\n                     \n                     \n                        \u2022Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients [see Warnings and Precautions (), Adverse Reactions (), Description ()].",
    "drug": [
        {
            "name": "fluticasone propionate and salmeterol",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5134"
        }
    ]
}